Brief: Medivir Selects Global CRO Partner For Phase 2B Study
19/06/2024 09:23
June 19 (Reuters) - Medivir AB MEDIVIR.ST :
* HAS SELECTED A GLOBAL CRO PARTNER FOR PLANNED PHASE 2B
STUDY
EVALUATING FOSTROXACITABINE BRALPAMIDE (FOSTROX) + LENVIMA®
VERSUS LENVIMA ALONE IN SECOND LINE HCC
Source text for Eikon: ID:nWkr86MR4W
Further company coverage: MEDIVIR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))